Holen Sie sich die Stockscreener-App
5.225
0.85%
-0.045
Vorhandelsmarkt:
5.61
0.385
+7.37%
Schlusskurs vom Vortag:
$5.27
Offen:
$5.25
24-Stunden-Volumen:
815.75K
Relative Volume:
1.24
Marktkapitalisierung:
$308.78M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
99.71
EPS:
0.0524
Netto-Cashflow:
$12.42M
1W Leistung:
-1.42%
1M Leistung:
+20.11%
6M Leistung:
+17.68%
1J Leistung:
+7.95%
1-Tages-Spanne:
$5.18
$5.33
1-Wochen-Bereich:
$4.89
$5.475
52-Wochen-Spanne:
$3.8092
$5.70
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vergleichen Sie VNDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.225 | 311.44M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Vanda Pharmaceuticals (VNDA) Soars After FDA Lifts Tradipitant H - GuruFocus
Vanda jumps as FDA lifts tradipitant partial clinical hold - Seeking Alpha
Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study - marketscreener.com
FDA lifts partial clinical hold on Vanda’s tradipitant for motion sickness - Investing.com India
FDA Lifts Hold on Vanda’s Tradipitant Trials - TipRanks
FDA Lifts Hold on Vanda Pharmaceuticals' (VNDA) Tradipitant Stud - GuruFocus
Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold By Investing.com - Investing.com Canada
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - PR Newswire
Will Vanda Pharmaceuticals Inc. (VM4) stock see insider accumulation2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Vanda Pharmaceuticals (VNDA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What insider trading reveals about Vanda Pharmaceuticals Inc. stockOil Prices & Verified Swing Trading Watchlist - Newser
Is Vanda Pharmaceuticals Inc. (VM4) stock attractive for growth fundsMarket Activity Report & Low Risk Growth Stock Ideas - Newser
Will Vanda Pharmaceuticals Inc. (VM4) stock benefit from mergersWeekly Stock Report & Weekly Setup with High ROI Potential - Newser
Can Vanda Pharmaceuticals Inc. (VM4) stock double in coming years2025 Risk Factors & Free Long-Term Investment Growth Plans - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to new regulations2025 Volatility Report & Daily Oversold Bounce Ideas - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock moves in volatile trading sessionsPortfolio Gains Summary & AI Optimized Trading Strategy Guides - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to weak economy - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to monetary easingProfit Target & Risk Controlled Stock Alerts - Newser
Will Vanda Pharmaceuticals Inc. stock pay special dividends - Newser
H.C. Wainwright reiterates Buy rating on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Vanda Pharmaceuticals (Nasdaq:VNDA) Provides Key Regulatory Update on Motion Sickness Therapy - Kalkine Media
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
FDA Extends Review of Vanda Pharmaceuticals' (VNDA) Tradipitant - GuruFocus
FDA re-review of Vanda tradipitant partial clinical hold extended - Seeking Alpha
Vanda Pharmaceuticals Updates on Tradipitant FDA Review - TipRanks
Vanda Pharmaceuticals provides regulatory update on Tradipitant for motion sickness - marketscreener.com
Vanda Pharmaceuticals (VNDA) Updates on Tradipitant for Motion S - GuruFocus
Vanda Pharmaceuticals Provides Regulatory Update On Tradipitant For Motion Sickness - TradingView
Vanda Pharmaceuticals Inc Provides Regulatory Update on Tradipitant - TradingView
Vanda (Nasdaq: VNDA) details FDA hold re-review, labeling talks on tradipitant NDA - Stock Titan
Published on: 2025-11-28 08:55:55 - moha.gov.vn
Will Vanda Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Sector Moves & Fast Gaining Stock Reports - BỘ NỘI VỤ
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder (PR Newswire) - Aktiellt
Vanda Sees Sales Jump, But Losses Also Pile Up - Finimize
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Vanda a new buy at B. Riley on 'historic discount' - MSN
Will Vanda Pharmaceuticals Inc. (VM4) stock test record highs in 2025Wall Street Watch & Capital Efficient Trade Techniques - newser.com
Vanda Pharmaceuticals Leads 3 Promising Penny Stocks - Yahoo Finance
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects - MSN
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality (NASDAQ:VNDA) - Seeking Alpha
Vanda Reports Big Win In Wegovy Support Study, Analysts UpbeatVanda Pharmaceuticals (NASDAQ:VNDA) - Benzinga
Is Vanda Pharmaceuticals Inc. (VM4) stock trading at attractive multiples2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Vanda Pharmaceuticals (VNDA): Evaluating Valuation After Successful Tradipitant Trial Results in GLP-1 Therapy Space - Yahoo Finance
Can Vanda Pharmaceuticals Inc. (VM4) stock withstand sector downturnsWeekly Profit Recap & Verified Technical Trade Signals - newser.com
Will Vanda Pharmaceuticals Inc. (VM4) stock announce special dividendRate Hike & Fast Exit Strategy with Risk Control - newser.com
Is Vanda Pharmaceuticals Inc. stock supported by innovation pipelineOptions Play & Weekly Return Optimization Plans - newser.com
Chart based analysis of Vanda Pharmaceuticals Inc. trendsWeekly Volume Report & Capital Protection Trading Alerts - newser.com
Will Vanda Pharmaceuticals Inc. stock benefit from infrastructure spending2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Can Vanda's Upcoming Milestones Unlock Significant Growth In 2026? - RTTNews
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):